Richard Saynor and Vinita Gupta appointed Chair and Vice-Chair of IGBA CEO Advisory Committee
Geneva, 18th October 2022
The International Generic and Biosimilar Medicines Association (IGBA) announced today that it has appointed a Chair and Vice-Chair for its newly established Committee. Richard Saynor, CEO of Sandoz, has been nominated as inaugural Chair, and Vinita Gupta, CEO of Lupin, has been appointed Vice-Chair, both effective January 1, 2023, for a term of one year.
The Advisory Committee consists of fourteen leading multinational generic and biosimilar companies from Canada, Europe, India, Israel, Japan, and the United States, and was set up in February this year as a forum for industry leaders to discuss broad, strategic issues, and to engage and position the industry on a range of critical policy matters. The creation of the Advisory Committee comes in response to calls from international organizations for a stronger involvement of top industry leaders in the work of IGBA and its member associations, to drive a strategic dialogue between the public and corporate sectors.
“The nomination of a Chair and Vice-Chair for the IGBA CEO Advisory Committee is another important step for our association, which will take our strategic dialogue on the role of the generic and biosimilar industry to a new level”, said Vivian Frittelli, IGBA Management Committee Chair.
Suzette Kox, IGBA Secretary-General added: “As the global umbrella organization for our regional and national member associations, IGBA aspires, with the direct involvement of the leading generic and biosimilar medicines companies, to become an integral part of the global health conversation and to ensure that generic and biosimilar medicines are central to global healthcare policy discussions.”
The role of the Chair of the Advisory Committee is to advise the IGBA Management Committee on proposed priority topics and to set up working groups as needed to achieve the goals that IGBA and the CEO Advisory Committee have agreed on for the term ahead. The Chair represents the consensus view of the Advisory Committee and anchors its meetings. The Vice-Chair supports the Chair in its work and is designated Chair for the following term.
Advisory Committee members:
Richard Saynor, Chief Executive Officer – Sandoz (incoming Chair IGBA CEO Advisory Committee)
Vinita Gupta, Chief Executive Officer – Lupin Ltd. (incoming Vice-Chair)
Chirag Patel, President and Co-Chief Executive Officer – Amneal Pharmaceuticals Inc.
Jeff Watson, President and Chief Executive Officer – Apotex Inc.
Samina Hamied, Executive Vice-Chairperson – Cipla Ltd.
Satish Reddy, Chairman – Dr. Reddy’s Laboratories Ltd.
Lucas Sigman, Chief Executive Officer – Insud Pharma S.L.
Markus Sieger, Chief Executive Officer – Polpharma Group
Peter Goldschmidt, Chief Executive Officer and Chairman Executive Board – STADA Arzneimittel AG
Dilip Shanghvi, Managing Director – Sun Pharmaceutical Industries Ltd.
Kåre Schultz, President and Chief Executive Officer – Teva Pharmaceuticals Industries Ltd.
David Peix, Chief Executive Officer – Towa Pharma International Holdings S.L.
Michael Goettler, Chief Executive Officer – Viatris Inc.
Pankaj Patel, Chairman – Zydus Lifesciences Ltd.
The International Generic and Biosimilar medicines Association (IGBA) strengthens cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. Adopting a patient-centric approach, IGBA works to improve patient access to quality-assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. For more details, regarding IGBA and its member associations, see the IGBA website at: www.igbamedicines.org.